Abbott Laboratories (ABT) Gross Margin (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Gross Margin data on file, last reported at 56.2% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 67.0% year-over-year to 56.2%; the trailing twelve-month figure through Mar 2026 stood at 56.26% (up 45.0% YoY), and the FY2025 full-year result was 56.42%, up 101.0% from the prior year.
• Gross Margin retreated to 56.2% in Q1 2026, from 57.05% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 58.07% in Q1 2022 to a low of 54.48% in Q4 2022.
• A 5-year average of 55.8% and a median of 55.57% in 2023 frame the typical range for Gross Margin.
• Peak annual rise in Gross Margin reached 457 bps in 2022, while the deepest fall reached 399 bps in 2022.
• Tracing ABT's Gross Margin over 5 years: stood at 54.48% in 2022, then gained by 2 bps to 55.51% in 2023, then retreated by 1 bps to 54.97% in 2024, then gained by 4 bps to 57.05% in 2025, then retreated by 1 bps to 56.2% in 2026.
• Business Quant data shows ABT's Gross Margin at 56.2% in Q1 2026, 57.05% in Q4 2025, and 55.36% in Q3 2025.